188 related articles for article (PubMed ID: 25808961)
1. The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas - A Case Report.
Grzbiela H; Tarnawski R; D'Amico A; Stąpór-Fudzińska M
Curr Radiopharm; 2015; 8(1):45-8. PubMed ID: 25808961
[TBL] [Abstract][Full Text] [Related]
2. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
Thorwarth D; Henke G; Müller AC; Reimold M; Beyer T; Boss A; Kolb A; Pichler B; Pfannenberg C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):277-83. PubMed ID: 21300465
[TBL] [Abstract][Full Text] [Related]
4. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
[TBL] [Abstract][Full Text] [Related]
5. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.
Gehler B; Paulsen F; Oksüz MO; Hauser TK; Eschmann SM; Bares R; Pfannenberg C; Bamberg M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2009 Nov; 4():56. PubMed ID: 19922642
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTA-peptide PET/CT for radiotherapy planning and evaluating treatment response in the management of meningiomas.
Usmani S; Jain A; Hashmi SF; Mula-Hussain L; Riyami KA; Abubakar S; Shamim MS
J Pak Med Assoc; 2023 Jun; 73(6):1340-1343. PubMed ID: 37427649
[TBL] [Abstract][Full Text] [Related]
7. Influence of
Stade F; Dittmar JO; Jäkel O; Kratochwil C; Haberkorn U; Debus J; Combs SE
Radiat Oncol; 2018 Apr; 13(1):58. PubMed ID: 29606149
[TBL] [Abstract][Full Text] [Related]
8. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET.
Combs SE; Welzel T; Habermehl D; Rieken S; Dittmar JO; Kessel K; Jäkel O; Haberkorn U; Debus J
Acta Oncol; 2013 Apr; 52(3):514-20. PubMed ID: 23402336
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas.
Nyuyki F; Plotkin M; Graf R; Michel R; Steffen I; Denecke T; Geworski L; Fahdt D; Brenner W; Wurm R
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):310-8. PubMed ID: 19763565
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy--a case series.
Graf R; Plotkin M; Steffen IG; Wurm R; Wust P; Brenner W; Budach V; Badakhshi H
Head Face Med; 2012 Jan; 8():1. PubMed ID: 22217329
[TBL] [Abstract][Full Text] [Related]
13.
Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous
Maclean J; Fersht N; Sullivan K; Kayani I; Bomanji J; Dickson J; O'Meara C; Short S
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):448-458. PubMed ID: 28433399
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results.
Afshar-Oromieh A; Wolf MB; Kratochwil C; Giesel FL; Combs SE; Dimitrakopoulou-Strauss A; Gnirs R; Roethke MC; Schlemmer HP; Haberkorn U
Neuro Oncol; 2015 Feb; 17(2):312-9. PubMed ID: 25008094
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
[TBL] [Abstract][Full Text] [Related]
17. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
Graf R; Nyuyki F; Steffen IG; Michel R; Fahdt D; Wust P; Brenner W; Budach V; Wurm R; Plotkin M
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):68-73. PubMed ID: 22575489
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
[TBL] [Abstract][Full Text] [Related]
19. Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients.
Thorwarth D; Müller AC; Pfannenberg C; Beyer T
Recent Results Cancer Res; 2013; 194():425-39. PubMed ID: 22918773
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of [
Milosevic A; Styczen H; Grueneisen J; Li Y; Weber M; Fendler WP; Kirchner J; Damman P; Wrede K; Lazaridis L; Glas M; Guberina M; Eckstein A; Blau T; Herrmann K; Umutlu L; Forsting M; Deuschl C; Schaarschmidt B
J Nucl Med; 2023 Aug; 64(8):1185-1190. PubMed ID: 37385668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
